Medically reviewed by: Last updated: Reviewed for: Clinical accuracy, alignment with current obesity-medicine guidance and FDA labeling, and JumpstartMD treatment protocols.
Evidence tier: A — Based directly on FDA prescribing information and pharmacokinetic data. Cluster: Special Populations.
In a Nutshell
GLP-1 and dual GIP/GLP-1 medications are not used during pregnancy, and current FDA labeling advises stopping them at least 2 months before you try to conceive — long enough for the drug to clear and to protect the earliest, most vulnerable weeks of fetal development 1, 2, 3. There is not enough human safety data, and animal studies showed fetal growth reductions and structural abnormalities at clinically relevant doses 3, 6. The two-month buffer is built around the medication's long half-life (about 5 days for tirzepatide, about 1 week for semaglutide), which means it takes roughly four to five weeks to fully wash out — plus an extra margin for timing and individual variation 3.
Two pregnancy-related issues are unique to tirzepatide (Mounjaro®, Zepbound®). First, it can reduce the absorption of oral birth control pills, so the label recommends backup or non-oral contraception for 4 weeks after starting and 4 weeks after each dose increase 1, 2. Second, the weight loss itself can restore ovulation in women who weren't ovulating regularly — the "Ozempic babies" phenomenon — meaning an unplanned pregnancy can happen at exactly the moment contraception is least reliable 5.
The practical takeaway: if there is any chance you may want to become pregnant, have this conversation with your clinician before you start treatment — pregnancy planning, the right contraception method, and a clean stop-date can all be built into your plan from day one.
Why GLP-1 Medications Are Not Used in Pregnancy
GLP-1 receptor agonists like semaglutide (Ozempic®, Wegovy®) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro®, Zepbound®) have not been studied in pregnant people, so their safety in pregnancy is unknown. The animal reproduction studies we do have showed fetal growth reductions and structural abnormalities at clinically relevant exposures 3, 6. The FDA labels therefore advise against use in pregnancy, and if you discover you are pregnant while taking one, the guidance is to stop it and contact your clinician promptly 3, 6.
There are also mechanism-based reasons to be cautious: these medications suppress appetite and produce weight loss — neither of which is appropriate during pregnancy, when steady weight gain and adequate nutrition support fetal development. The same caution extends to breastfeeding, where there is no human data on whether these drugs pass into breast milk, so the decision is individualized with your clinician 6. This is also where compounded versions deserve extra scrutiny — they aren't FDA-reviewed for the same labeling, dosing consistency, or warnings (see compounded semaglutide safety).
How Long Before Trying to Conceive Should You Stop a GLP-1?
Stop at least two months before you start trying to conceive. This is the timeframe reflected in U.S. labeling for both semaglutide and tirzepatide, and it is built on the drug's pharmacokinetics 1, 2, 3.
Here is the logic. A medication is considered largely cleared after about five half-lives:
- Tirzepatide has a half-life of roughly 5 days, so it takes about four to five weeks to wash out almost completely 1.
- Semaglutide has a longer half-life of about 1 week, which is why the Wegovy® label says to "discontinue at least 2 months before a planned pregnancy because of the long half-life of semaglutide" 3.
The two-month window deliberately adds a buffer on top of the washout time, accounting for individual differences in metabolism, the unpredictability of when conception happens, and the fact that the most critical window of early fetal development falls in weeks 3-8 — often before a woman knows she is pregnant. Planning the stop-date in advance also gives you and your clinician time to manage the weight regain that commonly follows discontinuation (see stopping GLP-1s and weight regain).
GLP-1s and Birth Control: The Tirzepatide Contraception Interaction
This is one of the most overlooked facts about tirzepatide. Like all drugs in this family, it slows gastric emptying — changing how quickly the stomach releases its contents into the intestine where oral drugs are absorbed. For most medications this effect is minor; for oral birth control pills, with tirzepatide specifically, it is not.
In the FDA pharmacology studies, a single 5 mg dose of tirzepatide taken with a combined oral contraceptive (0.035 mg ethinyl estradiol plus 0.25 mg norgestimate) reduced the peak blood levels (Cmax) of the hormones substantially 1, 2:
- Ethinyl estradiol: −59%
- Norgestimate: −66%
- Norelgestromin (norgestimate's active metabolite): −55%
Total exposure over time (AUC) dropped more modestly — about 20-23% — but the sharp drop in peak levels can be enough to compromise a pill's reliability, especially in the first weeks of a new dose 1, 2. This gastric-emptying effect is greatest after the first 5 mg dose and diminishes with subsequent doses, which is why the backup guidance is keyed to starting and to each dose increase rather than the whole treatment course 1.
This interaction is essentially unique to tirzepatide. Semaglutide — both Ozempic® and Wegovy® — was studied with ethinyl estradiol and levonorgestrel and did not affect oral-contraceptive absorption to any clinically relevant degree; no backup method is recommended on the semaglutide label for that reason 4. If reliable contraception while losing weight is a priority for you, that difference between the two drugs is worth raising with your clinician (see semaglutide vs. tirzepatide and our broader GLP-1 drug interactions guide).
How Long Should You Use Backup Contraception on Tirzepatide?
If you take an oral contraceptive and are starting tirzepatide, the FDA label recommends either switching to a non-oral method or adding a barrier method for:
Because tirzepatide is titrated upward over several months, those four-week windows can overlap repeatedly, so for many women it is simpler to switch to a method that bypasses the stomach entirely for the duration of treatment — an IUD (hormonal or copper), an implant, the patch, the vaginal ring, or injectable contraception. These work systemically rather than through intestinal absorption, so the pill-absorption issue does not apply. One more caution: vomiting and diarrhea during titration can independently reduce pill absorption, so if you stay on oral contraceptives, follow the missed-dose instructions on your pill packet whenever GI side effects strike (see nausea and digestive side effects).
The Fertility Rebound: "Ozempic Babies" Explained
You may have seen the headlines about "Ozempic babies" — unexpected pregnancies in women who had previously struggled to conceive. This is a real, biologically grounded phenomenon, but it has nothing to do with the drug being a fertility treatment. It is a downstream effect of weight loss and improved metabolic health 5.
Excess body fat and insulin resistance disrupt the hormonal signaling that drives ovulation — a leading mechanism behind infertility in polycystic ovary syndrome (PCOS) and obesity-related infertility. As weight comes down, fat-derived estrogen falls, insulin sensitivity improves, menstrual cycles often become more regular, and ovulation can resume — sometimes within weeks, and before a woman realizes it has happened 5.
That is the heart of the "Ozempic babies" story, and for tirzepatide users it creates a compounded risk: ovulation can return at the very same time the oral-contraceptive interaction is undermining the birth control pill. A woman who assumed she "couldn't get pregnant," and whose pill is quietly less effective, can conceive while still taking a medication that shouldn't be used in pregnancy. This is exactly why non-oral contraception is often the safer default during tirzepatide treatment.
The flip side is good news: for women who want to conceive, reaching a healthier weight first — under supervision, with a proper washout before trying — can improve fertility and reduce pregnancy complications. If menopause or perimenopause is also part of your picture, see GLP-1s and menopause and our cross-hub guides on perimenopause weight gain and visceral fat.
Is This Normal? When to Talk to Your Clinician
If you are of reproductive age and considering or already taking a GLP-1 medication for weight loss, pregnancy planning should be part of the conversation from the start. Bring it up if any of the following apply:
- You might want to become pregnant in the next year or two — your clinician can map a stop-date that respects the two-month washout.
- You rely on oral birth control pills and are on (or starting) tirzepatide — discuss a non-oral method or a defined backup window.
- You have PCOS, irregular cycles, or a history of obesity-related infertility, which can make a fertility rebound more likely if pregnancy is not your goal.
- Your cycles change after starting treatment — periods becoming more regular can signal that ovulation has resumed.
- You are breastfeeding and weighing whether to start or continue a GLP-1.
These are exactly the planning points a clinician who screens for eligibility and contraindications is there to handle.
Red Flags — Seek Care Now
- A positive home pregnancy test, or you think you may be pregnant, while taking a GLP-1. Stop the medication and contact your clinician the same day — do not wait for your next visit 3, 6.
- A missed period plus pregnancy symptoms (nausea unlike your usual GI side effects, breast tenderness, fatigue) — test and call.
- Severe, persistent vomiting or diarrhea while relying on the pill — your birth control may have failed; use a backup method and contact your clinician.
What You Can Do About It
1. Plan before you start. If pregnancy is anywhere on your horizon, tell your clinician at the first consultation, so the whole timeline — contraception method, stop-date, maintenance plan, and a healthy pre-pregnancy weight target — is built in from the beginning.
2. Choose contraception that fits the drug. On tirzepatide, the simplest reliable approach is usually a non-oral method (IUD, implant, patch, ring, or injection). If you stay on the pill, use a backup or barrier method for 4 weeks after starting and 4 weeks after each dose increase, and follow missed-dose rules during any vomiting or diarrhea 1, 2. On semaglutide the oral-contraceptive interaction is not a concern, but pregnancy planning still applies 4.
3. Give yourself a clean two-month washout. When you decide to try to conceive, stop at least two months ahead and confirm timing with your clinician 1, 2, 3. Use that window to transition to a maintenance plan so any regain after stopping is managed and your lean muscle mass is protected. Dosing changes, restart-after-pregnancy timing, and breastfeeding choices are all individualized — this is what medically supervised GLP-1 care is for.
Get Started with JumpstartMD
If you're losing weight on a GLP-1 and pregnancy is part of your future, you deserve a care team that plans for it from day one rather than reacting later. JumpstartMD was founded in 2007 by Stanford-trained physicians, with programs built around comprehensive labs, hormones, and body composition — and peer-reviewed outcomes published in the Journal of Obesity.
You're seen face-to-face by licensed clinicians — in person at our 14 California locations or online across California — so contraception, fertility goals, and a safe stop-date are real conversations, not afterthoughts. Care begins with a 69-biomarker lab screening and InBody® body composition scanning at your visit cadence, which tracks lean mass so you lose fat, not strength (without supervision, up to 40% of weight lost on GLP-1s can be muscle — and entering pregnancy strong matters).
Our clinicians manage the full picture: contraindication screening before any prescription, drug-interaction monitoring (including the tirzepatide–oral-contraceptive interaction), restart protocols, and a step-down/taper plan to protect your results through the washout window. FDA-approved options include Ozempic®, Wegovy®, Zepbound®, Mounjaro®, and Rybelsus®, alongside non-GLP-1 and no-medication plans, with flexible dosing, microdosing, and maintenance support. Pricing is personalized — you pay for the dose prescribed, not a flat monthly medication fee — and health coaching and nutrition guidance are included in membership.
Ready to build a plan that fits your fertility timeline? Schedule a free, no-obligation consultation by phone or through our online form — there's no commitment, just a clear conversation about what's right for you.
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Related Articles
- Who qualifies for GLP-1 treatment — where pregnancy plans and contraindication screening are first addressed.
- Dosing and titration — explains the dose-escalation schedule that the backup-contraception windows are keyed to.
- GLP-1 drug interactions — the broader picture of how delayed gastric emptying affects oral medications, including the pill.
- Stopping GLP-1s and weight regain — how to manage the washout window before conceiving without losing your progress.
- GLP-1s and menopause — the cross-hub bridge to hormonal weight change later in life.
- Semaglutide vs. tirzepatide — the contraception difference is one reason the choice between them matters.
Frequently Asked Questions
How long should I use backup contraception on tirzepatide?
If you take oral birth control pills, the FDA label for tirzepatide (Mounjaro®, Zepbound®) recommends either switching to a non-oral method or adding a barrier method for 4 weeks after you start tirzepatide and for 4 weeks after each dose increase 1, 2, because the drug sharply lowers the peak levels of the pill's hormones (ethinyl estradiol by 59%) 1. Since the dose is raised several times during titration, many women find it simpler to switch to an IUD, implant, patch, ring, or injection, which bypass the stomach. This interaction is specific to tirzepatide; semaglutide does not meaningfully affect oral contraceptives 4.
How long before trying to conceive should I stop tirzepatide?
At least two months before you try to conceive 1, 2. Tirzepatide has a half-life of about 5 days and takes roughly four to five weeks to clear; the two-month window adds a buffer for individual variation, the unpredictability of conception timing, and the critical early-pregnancy window (weeks 3-8) when a fetus is most vulnerable. Always confirm the exact timing with your clinician, who can also plan a maintenance strategy so you don't regain weight during the gap.
Is the contraception interaction the same for Ozempic and Wegovy?
No. It is specific to tirzepatide. Semaglutide (Ozempic®, Wegovy®) was tested with oral contraceptives and did not reduce their absorption to a clinically relevant degree, so no backup method is recommended on its label 4. The pre-conception washout still applies to both drugs.
Can a GLP-1 make me more fertile?
Indirectly, yes. They aren't fertility drugs, but the weight loss and improved insulin sensitivity they produce can restore regular ovulation in women with PCOS or obesity-related infertility — the "Ozempic babies" effect 5. That's good news if you're trying to conceive (after a proper washout), but it means unplanned pregnancy is a real risk if you assume you can't get pregnant. Reliable contraception matters while on treatment.
What should I do if I get pregnant while taking a GLP-1?
Can I take a GLP-1 while breastfeeding?
There is no human data on whether semaglutide or tirzepatide passes into breast milk, so the labels don't establish it as safe and the decision is individualized with your clinician 6.
References
- U.S. Food and Drug Administration, "Highlights of Prescribing Information: Mounjaro (tirzepatide) injection, for subcutaneous use," [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf. [Accessed: Jun. 10, 2026]. ↩
- U.S. Food and Drug Administration, "Highlights of Prescribing Information: Zepbound (tirzepatide) injection, for subcutaneous use," [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf. [Accessed: Jun. 10, 2026]. ↩
- U.S. Food and Drug Administration, "Highlights of Prescribing Information: Wegovy (semaglutide) injection, for subcutaneous use," [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf. [Accessed: Jun. 10, 2026]. ↩
- U.S. Food and Drug Administration, "Highlights of Prescribing Information: Ozempic (semaglutide) injection, for subcutaneous use," [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf. [Accessed: Jun. 10, 2026]. ↩
- H. Cena, L. Chiovato, R. E. Nappi, "Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists," The Journal of Clinical Endocrinology & Metabolism, vol. 105, no. 8, p. e2695, Aug. 2020, [Online]. Available: https://doi.org/10.1210/clinem/dgaa285. PMID: 32442310. [Accessed: Jun. 10, 2026]. ↩
- Organization of Teratology Information Specialists (OTIS)/MotherToBaby, "Tirzepatide (Mounjaro®, Zepbound®)," MotherToBaby Fact Sheets, NCBI Bookshelf, [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK605070/. [Accessed: Jun. 10, 2026]. ↩
